Search results

Found 9665 matches for

Researchers at the MRC Weatherall Institute of Molecular Medicine have recently discovered why a class of cancer drugs is beneficial only in a subset of patients. The results could pave the way for the future development of these drugs, known as PNP-inhibitors, as personalised medicines.

Digital illustration of a cancer cell and DNA strand

Andrew Armitage

M.Biochem, D.Phil Andrew Armitage - Senior Postdoctoral Scientist

Jana Koth

PhD, Dipl-Biol. Jana Koth - Imaging Facility Manager

Timothy Rostron

BSc; MSc Timothy Rostron - Sequencing and HLA Typing Laboratory Manager

Anne Farmer

Anne Farmer - MRC TIDU Executive Coordinator

Jo Hovard

Jo Hovard - IMD Business Manager

Thomas Milne

PhD Thomas Milne - Professor of Haematology

Sarah Gooding

Sarah Gooding - Clinician Scientist

Asger Jakobsen

BMBCh, MRCP, DPhil Asger Jakobsen - Postdoctoral Research Scientist

Marlen Metzner

BSc, MSc Marlen Metzner - Next Generation Sequencing Lead

Jim Hughes

Jim Hughes - Professor of Gene Regulation

Natalina Elliott

PhD-Cancer Biology, Vanderbilt University; BS-Recombinant Genetics & Chemistry, Western Kentucky University Natalina Elliott - Postdoctoral Researcher